Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Enrolling by invitation Not applicable

A Randomized, Comparative, Controlled Study of Differences in the Incidence of Postoperative Sore Throat (POST) by Inner Diameter Size of the TaperGuardTM Endotracheal Tube (ETT)

NCT07511998 · tracked via the Priya Life Science South Korea tracker
Sponsor
Kyungpook National University Chilgok Hospital
Phase
Not applicable
Started
2025-02-26
Last updated
2026-04-06

Condition(s) studied

Postoperative Sore ThroatHoarseness

Investigational drug(s) / intervention(s)

TaperGuard™ Endotracheal Tube

TaperGuard™ Endotracheal Tube: A tapered-cuff ETT. Cuff pressure is maintained at 22 cmH2O

Study summary

Postoperative sore throat (POST) is a common complication following general anesthesia involving endotracheal intubation, often leading to decreased patient satisfaction. The TaperGuard™ endotracheal tube (ETT) features a tapered-shaped cuff designed to reduce micro-aspiration and has been shown to result in a lower incidence of POST compared to conventional cylindrical ETTs. While previous studies using standard cylindrical ETTs suggested that a smaller inner diameter (ID) reduces the risk of POST, this relationship has not been fully established specifically for the TaperGuard™ ETT.

This study aims to compare the incidence of POST between a standard-sized TaperGuard™ ETT (ID 7.0 mm) and a smaller-sized TaperGuard™ ETT (ID 6.0 mm) in female patients. The investigators hypothesize that using a smaller ID TaperGuard™ ETT will significantly reduce the occurrence of POST within 24 hours after surgery.

Patients will be randomly assigned to either the control group (ID 7.0 mm) or the small group (ID 6.0 mm). Throughout the procedure, cuff pressure will be strictly maintained at 22 cmH2O to minimize mucosal damage. The primary outcome is the presence of sore throat, and secondary outcomes include the severity of the pain and the incidence of hoarseness at several time points up to 24 hours postoperatively.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Female patients. * Aged between 19 and 70 years. * American Society of Anesthesiologists (ASA) physical status I, II, or III. * Patients scheduled to undergo elective surgery under general anesthesia requiring endotracheal intubation. * Patients undergoing surgery in the supine or lithotomy position. * Patients who voluntarily provide written informed consent after receiving a full explanation of the study's purpose and procedures Exclusion Criteria: * Predicted difficult intubation. * Confirmed diseases or anatomical abnormalities of the head and neck, including the pharynx and larynx. * Presence of preoperative sore throat. * Risk of pulmonary aspiration. * Requirement for the prone position or other surgical positions where airway management with a TaperGuard™ ETT is difficult. * Scheduled for head and neck surgery or other procedures where the use of a TaperGuard™ ETT is challenging. * Potential pregnancy. * Inability to provide informed consent or make a decision to participate after receiving the study explanation

Primary outcome measure(s)

  • Incidence of Postoperative Sore Throat (POST) — Up to 24 hours after surgery (Assessment time points: immediately upon arrival at the Post-Anesthesia Care Unit [PACU], and at 1, 6, and 24 hours postoperatively)
    The presence or absence of sore throat (Yes/No) will be assessed by a blinded co-investigator

Trial sites (1)

FacilityCityRegionStatus
Kyungpook National University Chilgok Hospital Daegu Daegu
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07511998 on ClinicalTrials.gov ↗ ← All trials in South Korea